(GH) Guardant Health - Ratings and Ratios
Blood Tests, Tissue Tests, Genetic Panels, Liquid Biopsy, Screening
GH EPS (Earnings per Share)
GH Revenue
Description: GH Guardant Health
Guardant Health Inc (NASDAQ:GH) is a precision oncology company that offers a range of innovative blood and tissue tests, as well as data sets, to support cancer diagnosis, treatment, and research. The companys product portfolio includes various liquid biopsy tests, such as Guardant360 and GuardantOMNI, which provide insights into tumor molecular profiles and immune response. Additionally, Guardant Health offers development services, including companion diagnostic development and regulatory approval, to support biopharmaceutical companies.
From a business perspective, Guardant Healths revenue growth is driven by the increasing adoption of its precision oncology tests, particularly in the biopharmaceutical industry. Key performance indicators (KPIs) to watch include revenue growth rate, test adoption rates, and the number of biopharmaceutical partnerships. The companys ability to expand its product portfolio and enhance its data analytics capabilities will be critical to driving future growth. With a strong presence in the US and international markets, Guardant Health is well-positioned to capitalize on the growing demand for precision oncology solutions.
In terms of financials, Guardant Healths market capitalization stands at approximately $5.6 billion, with a return on equity (ROE) of 368.51%. While the companys P/E ratio is not available due to its current loss-making status, investors should monitor its revenue growth and operating expenses to gauge its path to profitability. Other key metrics to track include the companys cash burn rate, research and development (R&D) expenses, and sales and marketing expenses.
From a competitive perspective, Guardant Health operates in a rapidly evolving market, with a growing number of players competing for market share. The companys competitive advantage lies in its innovative product portfolio, strong partnerships with biopharmaceutical companies, and its ability to provide actionable insights to support cancer diagnosis and treatment. As the precision oncology market continues to grow, Guardant Healths ability to maintain its market position and expand its product offerings will be critical to its long-term success.
GH Stock Overview
| Market Cap in USD | 8,408m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2018-10-04 |
GH Stock Ratings
| Growth Rating | 13.4% |
| Fundamental | 33.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 132% |
| Analyst Rating | 4.50 of 5 |
GH Dividends
Currently no dividends paidGH Growth Ratios
| Growth Correlation 3m | 42.8% |
| Growth Correlation 12m | 85.4% |
| Growth Correlation 5y | -70.2% |
| CAGR 5y | -6.20% |
| CAGR/Max DD 5y | -0.07 |
| Sharpe Ratio 12m | 0.24 |
| Alpha | 132.22 |
| Beta | 1.636 |
| Volatility | 55.89% |
| Current Volume | 2864.5k |
| Average Volume 20d | 2512.9k |
| Stop Loss | 65.3 (-3.1%) |
| Signal | 3.28 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-413.8m TTM) > 0 and > 6% of Revenue (6% = 49.7m TTM) |
| FCFTA -0.21 (>2.0%) and ΔFCFTA 0.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 77.82% (prev 169.1%; Δ -91.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.18 (>3.0%) and CFO -238.5m > Net Income -413.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (124.1m) change vs 12m ago 1.36% (target <= -2.0% for YES) |
| Gross Margin 62.84% (prev 82.26%; Δ -19.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.36% (prev 40.00%; Δ 16.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -133.7 (EBITDA TTM -368.3m / Interest Expense TTM 3.06m) >= 6 (WARN >= 3) |
Altman Z'' -7.26
| (A) 0.48 = (Total Current Assets 883.4m - Total Current Liabilities 238.4m) / Total Assets 1.33b |
| (B) -2.08 = Retained Earnings (Balance) -2.77b / Total Assets 1.33b |
| warn (B) unusual magnitude: -2.08 — check mapping/units |
| (C) -0.28 = EBIT TTM -409.7m / Avg Total Assets 1.47b |
| (D) -1.70 = Book Value of Equity -2.78b / Total Liabilities 1.64b |
| Total Rating: -7.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.61
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -3.08% = -1.54 |
| 3. FCF Margin -33.17% = -7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -3.10 = -2.50 |
| 6. ROIC - WACC -54.19% = -12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 99.45% = 4.97 |
| 9. Rev. CAGR 28.12% = 2.50 |
| 10. EPS Trend 59.69% = 1.49 |
| 11. EPS CAGR 21.82% = 2.18 |
What is the price of GH shares?
Over the past week, the price has changed by +8.95%, over one month by +62.77%, over three months by +60.14% and over the past year by +174.40%.
Is Guardant Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GH is around 69.37 USD . This means that GH is currently overvalued and has a potential downside of 2.89%.
Is GH a buy, sell or hold?
- Strong Buy: 15
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.3 | -9% |
| Analysts Target Price | 61.3 | -9% |
| ValueRay Target Price | 78.8 | 16.9% |
Last update: 2025-08-30 10:00
GH Fundamental Data Overview
CCE Cash And Equivalents = 629.1m USD (Cash And Short Term Investments, last quarter)
P/S = 10.1438
P/B = 55.6696
Beta = 1.437
Revenue TTM = 828.8m USD
EBIT TTM = -409.7m USD
EBITDA TTM = -368.3m USD
Long Term Debt = 1.12b USD (from longTermDebt, last quarter)
Short Term Debt = 26.3m USD (from shortTermDebt, last quarter)
Debt = 1.14b USD (Calculated: Short Term 26.3m + Long Term 1.12b)
Net Debt = 705.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.92b USD (8.41b + Debt 1.14b - CCE 629.1m)
Interest Coverage Ratio = -133.7 (Ebit TTM -409.7m / Interest Expense TTM 3.06m)
FCF Yield = -3.08% (FCF TTM -274.9m / Enterprise Value 8.92b)
FCF Margin = -33.17% (FCF TTM -274.9m / Revenue TTM 828.8m)
Net Margin = -49.93% (Net Income TTM -413.8m / Revenue TTM 828.8m)
Gross Margin = 62.84% ((Revenue TTM 828.8m - Cost of Revenue TTM 308.0m) / Revenue TTM)
Tobins Q-Ratio = -3.21 (set to none) (Enterprise Value 8.92b / Book Value Of Equity -2.78b)
Interest Expense / Debt = 0.09% (Interest Expense 983.0k / Debt 1.14b)
Taxrate = 21.0% (US default)
NOPAT = -409.7m (EBIT -409.7m, no tax applied on loss)
Current Ratio = 3.71 (Total Current Assets 883.4m / Total Current Liabilities 238.4m)
Debt / EBITDA = -3.10 (Net Debt 705.0m / EBITDA -368.3m)
Debt / FCF = -4.15 (Debt 1.14b / FCF TTM -274.9m)
Total Stockholder Equity = -189.0m (last 4 quarters mean)
RoA = -31.07% (Net Income -413.8m, Total Assets 1.33b )
RoE = unknown (Net Income TTM -413.8m / Total Stockholder Equity -189.0m)
RoCE = -44.22% (Ebit -409.7m / (Equity -189.0m + L.T.Debt 1.12b))
RoIC = -43.58% (NOPAT -409.7m / Invested Capital 940.1m)
WACC = 10.61% (E(8.41b)/V(9.55b) * Re(12.04%)) + (D(1.14b)/V(9.55b) * Rd(0.09%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 5.11%
Discount Rate = 12.04% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -274.9m)
Revenue Correlation: 99.45 | Revenue CAGR: 28.12%
Rev Growth-of-Growth: 2.18
EPS Correlation: 59.69 | EPS CAGR: 21.82%
EPS Growth-of-Growth: -11.29
Additional Sources for GH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle